Patent details
93315 Product Name: Procédé de traitement de la sclérose multiple - Daclizumab
Basic Information
- Publication number:
- 93315
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP037621810
- Legal Status:
- Invalid
- Application number:
- 93315
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1107
- Marketing Authorization Type:
- Marketing Authorization Date:
- 05/07/2016
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
Dates
- Filing date:
- 17/11/2016
- First Marketing Authorization date:
- 05/07/2016
- Grant date:
- 26/01/2017
- Activation date:
- Publication date:
- 26/01/2017
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 27/06/2028
- SPC Extension Expiration:
- 27/06/2028
- Rejection date:
- Withdrawal date:
Owner
- From:
- 17/11/2016
- Name:
- THE GOV. OF THE USA, REPR. BY THE SECR., DEPT. OF HEALTH AND HUMAN SERV., NATIONAL INST. OF HEALTH
- Address:
- OFFICE OF TECHNOLOGY TRANSFER 6011 EXECUTIVE BOULEVARD, SUI, ROCKVILLE, MD 20814, United States (US)
Agent
- Name:
- DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
- From:
- 17/11/2016
- Address:
- PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
- To:
Inventor
1
- Name:
- MCFARLAND Henry, F.
- Address:
- United States (US)
2
- Name:
- MARTIN Roland
- Address:
- United States (US)
3
- Name:
- BIELEKOVA Bibiana
- Address:
- United States (US)
Publication
Bulletin
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2017/02
- Publication date:
- 22/06/2017
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 09/03/2017 | Certificate | 1 |
| 09/03/2017 | Publication | 1 |